Search
Azosemide
go.drugbank.com/drugs/DB08961InvestigationalAzosemide is a loop diuretic used to treat hypertension, edema, and ascites.
Stannsoporfin
go.drugbank.com/drugs/DB04912InvestigationalStannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing
Rhodamine B
go.drugbank.com/drugs/DB16853ExperimentalCategories: Compounds used in a research, industrial, or household settingDoramectin
go.drugbank.com/drugs/DB11400ExperimentalVet approvedin cattle. … Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Categories: Compounds used in a research, industrial, or household settingFucoxanthin
go.drugbank.com/drugs/DB15462InvestigationalIn vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. … Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).
Elsibucol
go.drugbank.com/drugs/DB05840Experimentalin chronic organ transplant rejection. … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common
Hymecromone
go.drugbank.com/drugs/DB07118InvestigationalCategories: Compounds used in a research, industrial, or household settingMirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the
Synonyms: myristoylated recombinant SCR1-3 of human complement reseptor type I